Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Oct 25, 2024
45:46
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
Oncology Today with Dr Neil Love